Pharmacology of PIEZO1 channels

Jacob A. Kinsella,Marjolaine Debant,Gregory Parsonage,Lara C. Morley,Muath Bajarwan,Charlotte Revill,Richard Foster,David J. Beech
DOI: https://doi.org/10.1111/bph.17351
IF: 7.3
2024-10-15
British Journal of Pharmacology
Abstract:PIEZO1 is a eukaryotic membrane protein that assembles as trimers to form calcium‐permeable, non‐selective cation channels with exquisite capabilities for mechanical force sensing and transduction of force into effect in diverse cell types that include blood cells, endothelial cells, epithelial cells, fibroblasts and stem cells and diverse systems that include bone, lymphatics and muscle. The channel has wide‐ranging roles and is considered as a target for novel therapeutics in ailments spanning cancers and cardiovascular, dental, gastrointestinal, hepatobiliary, infectious, musculoskeletal, nervous system, ocular, pregnancy, renal, respiratory and urological disorders. The identification of PIEZO1 modulators is in its infancy but useful experimental tools emerged for activating, and to a lesser extent inhibiting, the channels. Elementary structure–activity relationships are known for the Yoda series of small molecule agonists, which show the potential for diverse physicochemical and pharmacological properties. Intriguing effects of Yoda1 include the stimulated removal of excess cerebrospinal fluid. Despite PIEZO1's broad expression, opportunities are suggested for selective positive or negative modulation without intolerable adverse effects. Here we provide a focused, non‐systematic, narrative review of progress with this pharmacology and discuss potential future directions for research in the area.
pharmacology & pharmacy
What problem does this paper attempt to address?